aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechn

aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.11) per share which beat the analyst cons

Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase

Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvem

Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvem

Gainers AVITA Medical (NASDAQ:RCEL) stock moved upwards by 11.1% to $4.9 during Thursday's afte

aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.11) per share which beat the analyst cons

Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting wit

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biote

aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoido

aTyr Pharma NASDAQ: ATYR said it plans to conduct a new Phase III trial of efzofitimod in pulmonary

Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback.

aTyr Pharma (NASDAQ: ATYR) CEO Sanjay Shukla outlined the company's strategy to develop new therapie

aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.14) per share which beat the analyst cons

Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-F

aTyr Pharma, Inc. (NASDAQ: ATYR - Get Free Report) shares were down 2.1% during mid-day trading on T

SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Compan

SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biot

Meeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path f

AUSTIN, Texas, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company

aTyr Pharma, Inc. (NASDAQ: ATYR - Get Free Report) was the recipient of a significant drop in short

AUSTIN, Texas and DES MOINES, Iowa, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insuranc

SAN DIEGO , Dec. 15, 2025 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential derivative

SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential derivat

NEW YORK , Dec. 8, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, remi

NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareh

Here's a look at the top ten most shorted stocks in the market right now, including Wendy's,

RBC Capital analyst Brian Abrahams maintains aTyr Pharma (NASDAQ:ATYR) with a Sector Perform and

aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechn

Benzinga examined the prospects for many investors' favorite stocks over the last week — here&#3

Wells Fargo analyst Derek Archila downgrades aTyr Pharma (NASDAQ:ATYR) from Overweight to Equal-W

RBC Capital analyst Brian Abrahams downgrades aTyr Pharma (NASDAQ:ATYR) from Outperform to Sector

ATyr Pharma's stock dips after Phase 3 trial of efzofitimod misses steroid reduction goal, but s

Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS)